Over-the-Counter Monograph Drug User Fee Amendments
Sponsored By: Senator Jim Banks
In Committee
Summary
Creates a multi-year OTC monograph user-fee funding framework to fund FDA review of over-the-counter drugs. It also formalizes a pathway for prescription drugs to switch to nonprescription status and updates evidence standards for topical ingredients and sunscreens.
Show full summary
- Consumers and patients: Establishes a formal Rx-to-nonprescription switch pathway with mandatory guidance to improve predictability and require documented meetings and plans. The agency must publish a stakeholder engagement plan within 1 year and issue required guidance within 18 months.
- Industry and manufacturers: Reframes fees through FY2026–FY2030 with facility fees and order-request fees, year-by-year revenue targets, phased payment schedules, and a one-time workload adjustment tied to historical facility counts and arrears.
- Regulators and oversight: Requires expanded annual performance reports beginning FY2026, must be submitted within 120 days after each fiscal year end, public minutes of fee-negotiation meetings, and GAO assessments of the OTC supply chain and of Rx-to-nonprescription metrics.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
4 provisions identified: 2 benefits, 0 costs, 2 mixed.
Easier evidence rules for topical drugs
If enacted, FDA could use real-world evidence and accept non-animal testing alternatives when evaluating topical nonprescription active ingredients. FDA must issue draft guidance on non-animal testing within one year. The bill would treat testing methods that follow voluntary consensus standards as covered procedures. Final sunscreen orders must use historical safety data, consider SPF 15+ broad‑spectrum benefits, and follow the new evidence rules.
New Rx-to-OTC switch pathway
If enacted, sponsors planning to request a prescription‑to‑nonprescription switch could ask FDA for a written meeting to develop a plan and study design. FDA would document each meeting and must issue binding guidance within 18 months on evidentiary standards, label comprehension, and tools beyond the Drug Facts Label. FDA would also publish a stakeholder engagement plan within one year to identify switch candidates.
New OTC facility fees and timing
If enacted, the bill would make FDA set and publish annual OTC facility and order-request fees for FY2026–FY2030 using a specific formula. The formula would add inflation, reserve and direct-cost adjustments, and fixed dollar add-ons ($2,373,000 for FY2026; $1,233,000 for FY2027; $854,000 for FY2028). FDA could apply a one-time workload increase if average facility counts exceed 1,625 and arrears are under 30%. The bill would also change fee assessment periods and due dates and require fees to be set 60 days before each fiscal year. The statutory fee authority would end on October 1, 2030.
More OTC transparency and reports
If enacted, FDA would have to publish a yearly performance report within 120 days after each fiscal year, starting with FY2026. FDA would also post written minutes of fee-negotiation meetings within 30 days. The Government Accountability Office would have one year to report on Rx-to-nonprescription switch activity since Oct 1, 2022. The statute's specific reporting mandate would end on Jan 31, 2031.
Free Policy Watch
You just read the policy. Now see what it costs you.
Pick a topic. PRIA runs your household against live legislation and sends you a free personalized readout.
Pick a topic to get started
Sponsors & CoSponsors
Sponsor
Jim Banks
IN • R
Cosponsors
Timothy Kaine
VA • D
Sponsored 7/15/2025
Andy Kim
NJ • D
Sponsored 7/29/2025
Jon Husted
OH • R
Sponsored 7/29/2025
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govLive Policy Activity
LiveSurfaced from PRIA's policy knowledge graph — ranked by signal strength, connected by evidence.
Deep Dive
· Polipedia policy encyclopediaYouth Conservation Corps & Public Lands Corps
The federal government runs two closely related conservation-workforce pipelines on public lands: the Youth Conservation Corps YCC and the Public Lands Corps PLC. YCC is a summer employment program fo
WTO Membership & Uruguay Round Agreements Act
The Uruguay Round Agreements Act URAA of 1994 19 U.S.C. §§ 3501–3624 implemented U.S. membership in the World Trade Organization WTO and incorporated the Uruguay Round trade agreements — the broadest
World Trade Center Health Program (James Zadroga Act)
The World Trade Center Health Program is a federally funded health benefits program that provides free medical monitoring and treatment to those who were exposed to the toxic dust, debris, and fumes f
Workers' Compensation
Workers' compensation is the United States' primary workplace injury system — a no-fault insurance program where employees who are injured on the job receive medical coverage and partial wage replacem
Take It Personal
Get Your Personalized Policy View
Take the PRIA Score to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in